Literature DB >> 22826387

MR/PET: a new challenge in hybrid imaging.

Matthias K Werner1, Holger Schmidt, Nina F Schwenzer.   

Abstract

OBJECTIVE: This article provides a short overview of hybrid imaging and the potential advantages of combined MR/PET. We will address some of the challenges that had to be met before MR/PET could become clinically available as well as further scientific work that has to be done to increase the potential benefit of this emerging hybrid modality.
CONCLUSION: Hybrid imaging, the combination of two imaging modalities into one, promises the compensation of specific deficits of the modalities involved. PET/CT has gained wide acceptance for oncologic imaging in recent years; however, MRI has certain advantages that could make combined MR/PET more tempting in various clinical applications. The development of new clinical whole-body MR/PET systems offers new insights in metabolic and functional processes in oncology as well as cardiovascular and neurologic diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22826387     DOI: 10.2214/AJR.12.8724

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  10 in total

1.  Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.

Authors:  Byung Hyun Byun; Chang-Bae Kong; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Jae-Soo Koh; Soo-Yong Lee; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

2.  Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials.

Authors:  Sasan Partovi; Andres A Kohan; Lisa Zipp; Peter Faulhaber; Christos Kosmas; Pablo R Ros; Mark R Robbin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 3.  Utility of positron emission tomography-magnetic resonance imaging in musculoskeletal imaging.

Authors:  Ammar A Chaudhry; Maryam Gul; Elaine Gould; Mathew Teng; Kevin Baker; Robert Matthews
Journal:  World J Radiol       Date:  2016-03-28

Review 4.  Competitive advantage of PET/MRI.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Radiol       Date:  2013-06-18       Impact factor: 3.528

5.  Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup.

Authors:  Kerstin Zwirner; Daniela Thorwarth; René M Winter; Stefan Welz; Jakob Weiss; Nina F Schwenzer; Holger Schmidt; Christian la Fougère; Konstantin Nikolaou; Daniel Zips; Sergios Gatidis
Journal:  Strahlenther Onkol       Date:  2018-03-21       Impact factor: 3.621

6.  Image quality assessment of automatic three-segment MR attenuation correction vs. CT attenuation correction.

Authors:  Sasan Partovi; Andres Kohan; Chiara Gaeta; Christian Rubbert; Jose L Vercher-Conejero; Robert S Jones; James K O'Donnell; Patrick Wojtylak; Peter Faulhaber
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 7.  Functional magnetic resonance imaging in oncology: state of the art.

Authors:  Marcos Duarte Guimaraes; Alice Schuch; Bruno Hochhegger; Jefferson Luiz Gross; Rubens Chojniak; Edson Marchiori
Journal:  Radiol Bras       Date:  2014 Mar-Apr

8.  Correlative Imaging in a Patient with Cystic Thymoma: CT, MR and PET/CT Comparison.

Authors:  Valeria Romeo; Alfredo Esposito; Simone Maurea; Luigi Camera; Pier Paolo Mainenti; Giovannella Palmieri; Carlo Buonerba; Marco Salvatore
Journal:  Pol J Radiol       Date:  2015-01-13

Review 9.  MR-PET of the body: Early experience and insights.

Authors:  Miguel Ramalho; Mamdoh AlObaidy; Onofrio A Catalano; Alexander R Guimaraes; Marco Salvatore; Richard C Semelka
Journal:  Eur J Radiol Open       Date:  2014-09-16

10.  Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study.

Authors:  Concetta Schiano; Monica Franzese; Katia Pane; Nunzia Garbino; Andrea Soricelli; Marco Salvatore; Filomena de Nigris; Claudio Napoli
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.